Lung cancer is the leading cause of cancer-related death among men and women in the
United States. Approximately 80-85% of lung cancer cases are non–small-cell lung cancer …

Importance of the field: Non-small-cell lung cancer (NSCLC) is one of the most active fields
of research in oncology, with many drugs under clinical development. Most of these drugs …

Clinical trial data continue to emerge on treatments in advanced non-small cell lung cancer
(NSCLC), supporting the strategy that histology and molecular driver mutations should guide …

Importance of the field: Lung cancer is the most common cancer in the world today, in terms
of both incidence and mortality. Non-small-cell lung cancer (NSCLC) accounts for about …

Non–small-cell lung cancer is the leading cause of cancer-related death in men and women.
Because of its frequent presentation as advanced disease, most non–small-cell lung …

Many different targeted therapies with varying mechanisms of action have been added to
standard first‐line chemotherapy doublets in an effort to improve survival of patients with …

Lung cancer is the most common cause of cancer-related death worldwide, owing to its
metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care …

Lung cancer remains the leading cause of malignancy-related mortality worldwide, with over
one million cases diagnosed yearly. Non-small-cell lung cancer (NSCLC) accounts for> …

Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the
last two decades, with modest improvements in quality of life and overall survival. A plateau …

Conventional treatment of non-small-cell lung cancer (NSCLC) has apparently reached a
plateau of effectiveness in improving the survival of NSCLC patients. Although neoadjuvant …